全文获取类型
收费全文 | 179篇 |
免费 | 8篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 8篇 |
妇产科学 | 2篇 |
基础医学 | 20篇 |
口腔科学 | 1篇 |
临床医学 | 14篇 |
内科学 | 36篇 |
神经病学 | 14篇 |
特种医学 | 11篇 |
外科学 | 29篇 |
综合类 | 1篇 |
预防医学 | 15篇 |
眼科学 | 5篇 |
药学 | 9篇 |
中国医学 | 1篇 |
肿瘤学 | 19篇 |
出版年
2022年 | 2篇 |
2021年 | 3篇 |
2020年 | 3篇 |
2019年 | 4篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 4篇 |
2015年 | 3篇 |
2014年 | 4篇 |
2013年 | 9篇 |
2012年 | 10篇 |
2011年 | 6篇 |
2010年 | 6篇 |
2009年 | 12篇 |
2008年 | 8篇 |
2007年 | 11篇 |
2006年 | 11篇 |
2005年 | 8篇 |
2004年 | 17篇 |
2003年 | 14篇 |
2002年 | 7篇 |
2001年 | 5篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 1篇 |
1987年 | 1篇 |
1986年 | 1篇 |
1985年 | 2篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1977年 | 1篇 |
1972年 | 1篇 |
1971年 | 3篇 |
1969年 | 1篇 |
1968年 | 2篇 |
排序方式: 共有187条查询结果,搜索用时 31 毫秒
1.
Solyakov Lev Dobrota Dušan Drany Oleg Vachova Milena Machač Stanislav Mezešova Viera Bachurin Sergey Lombardi Vincenzo 《Molecular and chemical neuropathology / sponsored by the International Society for Neurochemistry and the World Federation of Neurology and research groups on neurochemistry and cerebrospinal fluid》1995,25(2-3):123-134
Molecular and chemical neuropathology - Changes in the functioning of the glutamatergic system in rabbit brain were studied after partial brain ischemia and reperfusion. In vitro studies were... 相似文献
2.
Marc P Pelletier Michael Coady Mahender Macha Philip E Oyer Robert C Robbins 《The Journal of heart and lung transplantation》2003,22(2):124-129
BACKGROUND: Multiple episodes of rejection following cardiac transplantation have been associated with an increased incidence of coronary atherosclerosis. Total lymphoid irradiation (TLI) has been shown to be a successful treatment for persistent allograft rejection, but its effect on coronary arterial disease has yet to be evaluated. METHODS: From 1987 to 1999, 40 patients required TLI for persistent or recurrent allograft rejection following heart transplantation. Each patient's (Group 1, n = 31) post-transplant coronary angiograms were examined and compared with those of a control group (Group 2, (n = 32) matched for time of transplantation. Degree of coronary stenosis was assessed on a 6-point scale. All patients received induction therapy (rabbit anti-thymocyte globulin or OKT3) and standard triple immunosuppressive therapy. TLI (80 cGy x 10 fractions) was used for the treatment of recurrent or persistent rejection on the basis of clinical indications. Actuarial survival, number and treatment of rejection episodes, and severity of coronary artery disease were compared in each group. RESULTS: Recipient gender, age, race and cytomegalovirus (CMV) status at time of transplant, along with donor gender, CMV status and graft ischemia time, were similar in both groups. Group 1 donor age was younger than that of Group 2 (22.2 +/- 11.2 vs 31.5 +/- 13.6 years, p = 0.004), and the indication for surgery in Group 1 patients was more likely to be ischemic heart disease (15 of 31 vs 6 of 32, p = 0.02). Mean follow-up was 5.7 +/- 3.5 years in Group 1 vs 6.9 +/- 3.8 in Group 2 (p = NS). Group 1 had more rejection episodes (4.4 +/- 2.2 vs 2.3 +/- 2.0, p = 0.0002) and more steroid treatments (9.78 +/- 4.0 g vs 5.14 +/- 4.7 g, p < 0.0001), but less coronary artery disease compared with Group 2 (p = 0.035). CONCLUSIONS: Despite multiple episodes of rejection, patients treated with TLI after cardiac transplant appear to develop less coronary atherosclerosis than appropriately matched controls. 相似文献
3.
Kennedy D Silver MM Winsor EJ Toi A Provias J Macha M Precht K Ledbetter DH Chitayat D 《American journal of medical genetics》2000,91(3):167-170
A fetus with lobar holoprosencephaly and lumbosacral meningomyelocele associated with duplication of the short arm of chromosome 3 is reported. The anomalies were detected on fetal ultrasound at 20 weeks' gestation and the autopsy findings correlated well with the prenatal findings. The fetal karyotype was 46,XY,der(3)del(3)(p26) dup(3)(p26p21.3). The association of holoprosencephaly with duplication 3p is well known, but to the best of our knowledge this is the first reported association of meningomyelocele with 3p duplication. These findings suggest that a gene or genes with a crucial role in central nervous system development are located on the short arm of chromosome 3. 相似文献
4.
Two paralogous mitochondrial malate dehydrogenase 2 (Mdh2) genes of Xenopus laevis have been cloned and sequenced, revealing 95% identity. Fluorescence in-situ hybridization (FISH) combined with tyramide amplification discriminates both genes; Mdh2a was localized into chromosome q3
and Mdh2b into chromosome q8. One kb cDNA probes detect both genes with 85% accuracy. The remaining signals were on the paralogous
counterpart. Introns interrupt coding sequences at the same nucleotide as defined for mouse. Restriction polymorphism has
been detected in the first intron of Mdh2a, while the individual variability in intron 6 of Mdh2b gene is represented by an
insertion of incomplete retrotransposon L1Xl. Rates of nucleotide substitutions indicate that both genes are under similar
evolutionary constraints. X. laevis Mdh2 genes can be used as markers for physical mapping and linkage analysis. 相似文献
5.
Mahender Nath Avula Archana Nagaraja Rao Lawrence D. McGill David William Grainger Florian Solzbacher 《Biomaterials》2013
The host foreign body response (FBR) adversely effects the performance of numerous implanted biomaterials especially biosensors, including clinically popular glucose-monitoring sensors. Reactive formation of a fibrous capsule around implanted sensors hinders the transport of essential analytes to the sensor from the surrounding tissue, resulting in loss of glucose response sensitivity and eventual sensor failure. Several strategies have sought to mitigate the foreign body response's effects on CGM sensors through the use of local delivery of pharmaceuticals and biomolecules with limited success. This study describes release of a tyrosine kinase inhibitor – masitinib – from the sensor implant to target tissue resident mast cells as key mediators of the FBR. Model implants are coated with a composite polymer hydrophilic matrix that rapidly dissolves upon tissue implantation to deposit slower-degrading polymer microparticles containing masitinib. Matrix dissolution limits coating interference with sensor function while establishing a local controlled-release delivery depot formulation to alter implant tissue pharmacology and addressing the FBR. Drug efficacy was evaluated in a murine subcutaneous pocket implant model. Drug release extends to more than 30 days in vitro. The resulting FBR in vivo, evaluated by implant capsule thickness and inflammatory cell densities at 14, 21, and 28 days, displays statistically significant reduction in capsule thickness around masitinib-releasing implant sites compared to control implant sites. 相似文献
6.
Stanislav Machač Jiří Radvanský Pavel Kolář Jiří Kříž 《The journal of spinal cord medicine》2013,36(4):412-420
Context/Objective: Traumatic damage to the cervical spinal cord is usually associated with a disruption of the autonomic nervous system (ANS) and impaired cardiovascular control both during and following exercise. The magnitude of the cardiovascular dysfunction remains unclear. The aim of the current study was to compare cardiovascular responses to peak voluntary exercise in individuals with tetraplegia and able-bodied participants.Design: A case-control study.Subjects: Twenty males with cervical spinal cord injury (SCI) as the Tetra group and 27 able-bodied males as the Control group were included in the study.Outcome Measures: Blood pressure (BP) response one minute after the peak exercise, peak heart rate (HRpeak), and peak oxygen consumption (VO2peak) on an arm crank ergometer were measured. In the second part of the study, 17 individuals of the Control group completed the Tetra group's workload protocol with the same parameters recorded.Results: There was no increase in BP in response to the exercise in the Tetra group. Able-bodied individuals exhibited significantly increased post-exercise systolic BP after the maximal graded exercise test (123±16%) and after completion of the Tetra group's workload protocol (114±11%) as compared to pre-exercise. The Tetra group VO2peak was 59% and the HRpeak was 73% of the Control group VO2peak and HRpeak, respectively.Conclusions: BP did not increase following maximal arm crank exercise in males with a cervical SCI unlike the increases observed in the Control group. Some males in the Tetra group appeared to be at risk of severe hypotension following high intensity exercise, which can limit the ability to progressive increase and maintain high intensity exercise. 相似文献
7.
Matthew M Riggs Leo J Seman Alexander Staab Thomas R MacGregor William Gillespie Marc R Gastonguay Hans J Woerle Sreeraj Macha 《British journal of clinical pharmacology》2014,78(6):1407-1418
Aims
To provide model-based clinical development decision support including dose selection guidance for empagliflozin, an orally administered sodium glucose cotransporter 2 inhibitor, through developed exposure−response (E−R) models for efficacy and tolerability in patients with type 2 diabetes mellitus (T2DM).Methods
Five randomized, placebo-controlled, multiple oral dose studies of empagliflozin in patients with T2DM (n = 974; 1–100 mg once daily, duration ≤12 weeks) were used to develop E−R models for efficacy (glycosylated haemoglobin [HbA1c], fasting plasma glucose [FPG] and urinary glucose excretion). Two studies (n = 748, 12 weeks) were used to evaluate tolerability E−R.Results
The efficacy model predicted maximal decreases in FPG and HbA1c of 16% and 0.6%, respectively, assuming a baseline FPG concentration of 8 mm (144 mg dl−1) and 10–25 mg every day empagliflozin targeted 80–90% of these maximums. Increases in exposure had no effect on incidence rates of hypoglycaemia (n = 4), urinary tract infection (n = 17) or genital/vulvovaginal-related (n = 16) events, although low prevalence rates may have precluded more accurate evaluation.Conclusions
E−R analyses indicated that 10 and 25 mg once daily empagliflozin doses achieved near maximal glucose lowering efficacy. 相似文献8.
David J. Seiffge MD Gian Marco De Marchis MD Masatoshi Koga MD PhD Maurizio Paciaroni MD Duncan Wilson PhD Manuel Cappellari MD Kosmas Macha MD Georgios Tsivgoulis MD Gareth Ambler PhD Shoji Arihiro MD Leo H. Bonati MD Bruno Bonetti MD Bernd Kallmünzer MD Keith W. Muir MD PhD Paolo Bovi MD Henrik Gensicke MD Manabu Inoue MD Stefan Schwab MD Shadi Yaghi MD Martin M. Brown MD PhD FRCP Philippe Lyrer MD Masahito Takagi MD PhD Monica Acciarrese MD Hans Rolf Jager MD FRCP Alexandros A. Polymeris MD Kazunori Toyoda MD PhD Michele Venti MD Christopher Traenka MD Hiroshi Yamagami MD PhD Andrea Alberti MD Sohei Yoshimura MD PhD Valeria Caso MD Stefan T. Engelter MD David J. Werring MD PhD FRCP the RAF RAF-DOAC CROMIS- SAMURAI NOACISP Erlangen and Verona registry collaborators 《Annals of neurology》2020,87(5):677-687
9.
Stoll Svenja Macha Kosmas Marsch Armin Gerner Stefan T. Siedler Gabriela Fröhlich Kilian Volbers Bastian Strasser Erwin F. Schwab Stefan Kallmünzer Bernd 《Journal of neurology》2020,267(7):2007-2012
Journal of Neurology - Oral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation require dose adjustment based on certain clinical criteria, but the off-label use of the reduced... 相似文献
10.
R Rosell U Gatzemeier D C Betticher U Keppler H N Macha R Pirker P Berthet J L Breau P Lianes M Nicholson A Ardizzoni A Chemaissani J Bogaerts G Gallant 《Annals of oncology》2002,13(10):1539-1549
BACKGROUND: The combination of paclitaxel with cisplatin or carboplatin has significant activity in non-small-cell lung cancer (NSCLC). This phase III study of chemotherapy-na?ve advanced NSCLC patients was designed to assess whether response rate in patients receiving a paclitaxel/carboplatin combination was similar to that in patients receiving a paclitaxel/cisplatin combination. Paclitaxel was given at a dose of 200 mg/m(2) (3-h intravenous infusion) followed by either carboplatin at an AUC of 6 or cisplatin at a dose of 80 mg/m(2), all repeated every 3 weeks. Survival, toxicity and quality of life were also compared. PATIENTS AND METHODS: Patients were randomised to receive one of the two combinations, stratified according to centre, performance status, disease stage and histology. The primary analyses of response rate and survival were carried out on response-evaluable patients. Survival was also analysed for all randomised patients. Toxicity analyses were carried out on all treated patients. RESULTS: A total of 618 patients were randomised. The two treatment arms were well balanced with regard to gender (83% male), age (median 58 years), performance status (83% ECOG 0-1), stage (68% IV, 32% IIIB) and histology (38% squamous cell carcinoma). In the paclitaxel/carboplatin arm, 306 patients received a total of 1311 courses (median four courses, range 1-10 courses) while in the paclitaxel/cisplatin arm, 302 patients received a total of 1321 courses (median four courses, range 1-10 courses). In only 76% of courses, carboplatin was administered as planned at an AUC of 6, while in 96% of courses, cisplatin was given at the planned dose of 80 mg/m(2). The response rate was 25% (70 of 279) in the paclitaxel/carboplatin arm and 28% (80 of 284) in the paclitaxel/cisplatin arm (P = 0.45). Responses were reviewed by an independent radiological committee. For all randomised patients, median survival was 8.5 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm [hazard ratio 1.20, 90% confidence interval (CI) 1.03-1.40]; the 1-year survival rates were 33% and 38%, respectively. On the same dataset, a survival update after 22 months of additional follow-up yielded a median survival of 8.2 months in the paclitaxel/carboplatin arm and 9.8 months in the paclitaxel/cisplatin arm (hazard ratio 1.22, 90% CI 1.06-1.40; P = 0.019); the 2-year survival rates were 9% and 15%, respectively. Excluding neutropenia and thrombocytopenia, which were more frequent in the paclitaxel/carboplatin arm, and nausea/vomiting and nephrotoxicity, which were more frequent in the paclitaxel/cisplatin arm, the rate of severe toxicities was generally low and comparable between the two arms. Overall quality of life (EORTC QLQ-C30 and LC-13) was also similar between the two arms. CONCLUSIONS: This is the first trial comparing carboplatin and cisplatin in the treatment of advanced NSCLC. Although paclitaxel/carboplatin yielded a similar response rate, the significantly longer median survival obtained with paclitaxel/cisplatin indicates that cisplatin-based chemotherapy should be the first treatment option. 相似文献